美诺华(603538.SH)：全资子公司获得利奥西呱片药品注册证书

Group 1 - The core point of the article is that Meinuohua's subsidiary has received approval from the National Medical Products Administration for the registration of Liosiguap tablets, enhancing the company's market competitiveness and product pipeline [1][3]. Group 2 - The drug is indicated for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) [2]. - Liosiguap acts as a soluble guanylate cyclase (sGC) agonist, which plays a crucial role in the pulmonary circulation system by catalyzing the synthesis of cyclic guanosine monophosphate (cGMP) [2]. - The company has invested approximately RMB 6.8671 million in the research and development of Liosiguap tablets as of the announcement date [2].